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Hormonal Management of Advanced Adenocarcinoma of the Prostate 
Brian J. Miles, MD* 
S ince 1941 when Huggins and Hodges (1) demonstrated that carcinoma of the prostate is a hormonally responsive tumor, 
castration or other methods of hormonal ablation have been the 
mainstay of deatment for advanced adenocarcinoma ofthe pros-
tate. While orchiectomy remains the gold standard for hormonal 
manipulation, alternative treatment methods include di-
ethylstilbestrol (DES), luteinizing hormone-releasing hormone 
(LHRH) agonists, and antiandrogens. 
Orchiectomy/DES 
Despite much early hope, numerous clinical trials over the 
past four decades have shown that cures and improved survival 
with castration and DES are unlikely. The largest series included 
studies by Nesbit and Baum (2) in the 1940s and early 1950s and 
the Veterans Administration Cooperative Urological Research 
Group (VACURG) studies in the 1960s (3). 
The cooperative study by Nesbit and Baum (2) in 1950 com-
pared patients with metastatic disease treated by either orchiec-
tomy, DES (1 to 5 mg/day), or a combination of DES and or-
chiectomy. These 263 patients were followed for five years and 
compared to a control group of 231 patients followed between 
1925 and 1940 who received no hormonal manipulation. Results 
revealed differences in ultimate survival between the hor-
monally treated group and the control group at five years (17% 
versus 6%). Patients treated with orchiectomy or a combination 
of DES and orchiectomy had the highest survival rate (20% and 
21%, respectively), whereas no difference was observed be-
tween the DES and control groups (10% versus 6%). However, 
because the control group was a historical series and not concur-
rent with the study group, it was difficult for the investigators to 
conclude, in that preantibiotic era, that the increase in survival 
was totally due to hormonal manipulation even though it oc-
curred in late and not early stages of the disease. 
In the VACURG study (3) 772 patients were randomly placed 
in four treatment groups: placebo, orchiectomy, DES (5 mg/ 
day), or a combination of orchiectomy and DES. All patients 
were followed for five years. Results revealed no statistical dif-
ference in survival between the four groups and showed that hor-
monal manipulation is palliative. The results also indicated that 
ultimate survival is apparentiy independent of the timing of hor-
monal manipulation. Although this study forms the basis for 
current clinical use of hormonal manipulation, it was not well 
designed. Patients were evaluated based on the original group to 
which they were assigned even if their treatment had been 
changed because they did not do well with the assigned method 
of treatment. The results, therefore, are extremely difficult to 
interpret. 
Nonetheless, these results were corroborated in 1982 by 
Lepor et al (4) who also used a historical control group to com-
pare ultimate survival to a group of patients with metastatic dis-
ease who received standard hormonal therapy. The results 
showed no significant difference in ultimate survival between 
the two groups. 
Based on the preponderance of evidence, the timing of hor-
monal intervention is not significant in asymptomatic patients 
with advanced stage D-2 prostate carcinoma. The only question 
remaining concems the significance of early hormonal interven-
tion in patients with stage D-1 disease and questionably minimal 
stage D-2 disease (5). In stage D-2 disease palliation is the only 
definitive indication for the use of hormonal ablation. Unfortu-
nately, the decision to hormonally ablate an asymptomatic pa-
tient with stage D-2 disease is often made without consideration 
of quality-of-life issues, such as the individual's sex life. In 
these circumstances physicians undoubtedly provide a disser-
vice to these patients. 
Orchiectomy remains the gold standard for hormonal manip-
ulation in adenocarcinoma of the prostate. It is definitive, allevi-
ates concerns about patient compliance, has the fewest long-
term side effects, and is performed easily with the patient under 
local anesthesia. In my practice the majority of men are not trou-
bled by the notion of castration or related body image changes 
when they understand all the treatment options and why orchiec-
tomy is necessary in their case. 
The main alternative to castration is DES. The VACURG 
study (3) proved that 3 mg/day of DES is the safest dose that 
provides a persistent and well-defined therapeutic response. 
However, the side effects from DES are substantial. The Leu-
prolide Study Group (6) found a 31% overall severe complica-
tion rate in patients on DES and a 27% severe complication rate 
in asymptomatic patients with no prior cardiac history. De Voogt 
et al (7) and Henriksson and Edhag (8) found similar significant 
complication rates with DES. This significant morbidity and 
mortality should relegate DES to a secondary role in the man-
agement of prostate cancer. 
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LHRH Agonists 
Despite its significant side effects, DES was the only alter-
native to castration until this decade when a new class of dmgs 
was developed. These LHRH agonists include naferelin, leu-
prolide, buserelin, and zoladex (6,9). Although only leuprolide 
is clinically available, the other dmgs are in various stages of 
study. Leuprolide differs from tme LHRH by a change in the 6 
position from gly to D-leu and in the 10 position from gly-NHj to 
NH, NHCH2CH3. The site of action is the pituitary. The sub-
stance is an agonist of gonadotropin releasing hormone, but par-
adoxically with chronic use is antagonistic to normal LHRH ef-
fects and achieves castrate testosterone levels within one month. 
The Leuprolide Study Group (6) evaluated 199 patients with new 
stage D-2 prostate cancer who received either 3 mg/day of DES 
or 1 mg/day of lupron injected subcutaneously. At two years the 
progression and survival rates were not significantly different. 
The increased cardiovascular morbidity and mortality suffered 
by patients on DES was significant. 
The principal side effects of LHRH agonists include hot 
flashes (up to 90%), fluid retention (2%), and gynecomastia 
(3%). Of more than 75 patients at Henry Ford Hospital receiving 
leuprolide, none have had any difficulty or shown any reluc-
tance in giving themselves injections. Leuprolide's associated 
morbidity and its similar efficacy to DES make it the best alter-
native to orchiectomy in the management of advanced car-
cinoma of the prostate. 
Antiandrogens 
The antiandrogens used for hormonal manipulation consist of 
three groups: steroidal, nonsteroidal, and those that inhibit 
steroidogenesis (10). 
The steroidal agents have both central and peripheral effects: 
centrally they decrease the LH levels, and peripherally they 
compete with dihydrotestosterone. The three major steroidal 
antiandrogens are cyproterone acetate (CPA), megestrol, and 
medroxyprogesterone acetate (MPA). CPA, which has gener-
ated the most interest, acts by blocking the uptake of di-
hydrotestosterone by the prostate (7,11). While use of megestrol 
is fairly common, in time it becomes ineffective due to a central 
escape phenomenon whereby the body overrides the com-
petitive blockade at the pituitary level. The central escape phe-
nomenon is also associated with CPA, but the dmg's strong pe-
ripheral effects compensate for this effect. In a phase III trial 
comparing CPA, MPA, and DES, Jacobi et al (11) found five-
year survival rates to be 38% for DES, 32% for CPA, but only 
14% for MPA. They also found that at three years the progres-
sion rate was 55% for DES, 80% for CPA, and 90% for MPA. 
Thus, DES was significandy better than either CPA or MPA in 
retarding progression. However, the cardiovascular toxicity was 
35% for DES patients and only 10% for CPA patients. Although 
antiandrogens have a limited role as primary hormonal ablaters, 
if orchiectomy is impossible they are of value because of the sig-
nificantly lower cardiovascular toxicity compared to DES. 
Nonsteroidal antiandrogens have significant peripheral ef-
fects. They are especially acceptable as a primary treatment be-
cause semm testosterone does not decrease and sexual potency 
is usually preserved. However, the primary response rate is only 
Table 
Summary of Initial Objective Response Rates* 
Number of % Objective 
Treatment Patients Response Range 
DES/Orchiectomy 177 83% 80.7-100 
Antiandrogens 
Cyproterone acetate 51 80% 65.0-100 
Flutamide 179 85% 53.8-100 
Ketoconazole 53 79% 72.5-100 
LHRH analog 191 83% 78.2-86 
*From Schuize H. Isaacs JT. Coffery DS. A crifical review of the concept of total an-
drogen ablation in the treatment of prostate cancer In: Murphy GP. ed. Prostate cancer Part 
A: Research, endocrine treatment and histopathology. New York: Alan Liss. Inc. 1987:1-19. 
60% to 70%, which generally is not prolonged due to in-
complete androgen blockade by these medications (12). 
The nonsteroidal antiandrogens include flutamide and 
RU-23908, a new dmg currently under study. The side effects of 
flutamide include severe diarrhea (30%), nausea and vomiting 
(30%), and gynecomastia (36%). In clinical use diarrhea is the 
primary side effect but usually resolves with dose modification. 
RU-23908 has a greater range of toxicity including night blind-
ness, interstitial pneumonitis (which is reversible but occasion-
ally fatal), and alcohol intolerance. Although not yet available 
clinically, its associated side effects will limit its use. 
The nonsteroidal antiandrogens should not be considered for 
primary hormonal ablation. They are currently used only in an 
attempt to achieve further palliation in patients whose initial hor-
mone treatment failed. They are also being evaluated in clinical 
trials in conjunction with orchiectomy or chemical castration in 
order to achieve "total" androgen ablation as a primary 
treatment. 
The two most important antiandrogens that inhibit ste-
roidogenesis are aminoglutethimide and ketoconazole (13-16). 
Ketoconazole impairs the activity of cytochrome P450-depen-
dent enzymes (15) and induces a rapid and sustained decrease in 
testicular and adrenal androgen production. Castrate levels of 
testosterone are usually achieved within four to eight hours after 
an initial dose of400 g. The usual dosage is 200 to 300 mg every 
eight hours. The principal side effect is nausea (20%), but hepa-
totoxicity, which is reversible, can occur although rarely 
(1/16,000) (15). 
Ketoconazole is a popular treatment option for patients in 
whom hormonal manipulation has failed. There is marked sub-
jective response (relief of pain, increased appetite, and im-
proved sense of well being) to treatment in about 50% of pa-
tients. Trachtenberg and Pont (14) suggest that this symptomatic 
improvement is probably mediated through a combination of 
diminishing androgen levels and also by the effects on the 
cytochrome P450 system. 
A summary comparison of initial objective (complete and 
partial) response rates for these various treatment modalities is 
presented in the Table. 
Total Hormonal Ablation 
In 1985 Labrie et al (17) reintroduced the concept of total an-
drogen ablation in the primary management of metastatic or lo-
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cally advanced adenocarcinoma of the prostate. After the initial 
work of Huggins and Hodges (1), investigators believed that the 
adrenal gland produced more androgen after orchiectomy and 
that the increased androgen levels were responsible for reactiva-
tion of prostate carcinoma in patients whose hormonal therapy 
failed. Recent studies, however, revealed that androgen levels 
remain normal in hormonally treated patients (18). Schuize et al 
(19) reviewed the results of hypophysectomy and adrenalectomy 
for therapeutic response in those patients whose standard hor-
monal therapy failed. In their summary of the results of seven 
studies of bilateral adrenalectomy, the 89 evaluable patients 
showed only a 5.6% objective response rate. The 209 padents 
from the seven studies of hypophysectomy yielded only a 6.7% 
response rate. 
These studies indicate that removal of circulating androgens 
after failure of hormonal treatment has no significant impact on 
the prostate carcinoma. However, this does not negate the hy-
pothesis of Labrie et al (17) that total hormonal ablation at the 
dme of initial treatment for metastatic disease will have a more 
significant impact than sequential therapy. Animal research has 
been performed to test this hypothesis. Studies of rat prostate 
cancer by Ellis and Isaacs (20) and by Redding and Schally (21) 
showed no significant difference in tumor response to castration 
versus castration plus antiandrogens or LHRH treatment versus 
LHRH plus antiandrogens. Both studies reported a similar re-
sponse for castration/LHRH agonists alone or in combination 
with antiandrogens. In clinical trials comparing orchiectomy 
and CPA, Giuliani et al (22) found one- and two-year survival 
rates equal to those found by Murphy et al (23) with DES and 
orchiectomy. Schroeder et al (24) reported these same results 
when comparing LHRH agonist versus LHRH plus CPA. 
These studies strongly indicate that combined initial therapy 
for metastatic disease provides no treatment or survival advan-
tage. Early results from a National Cancer Institute sponsored 
double-blind intergroup study comparing leuprolide plus 
placebo to leuprolide plus flutamide suggest a slightly increased 
disease-free period of approximately 11 weeks for those on com-
bined treatment (personal communication, E.D. Crawford). 
However, until survival data are available, this mode of therapy 
cannot be considered superior 
Conclusions 
Orchiectomy remains the gold standard for treating advanced 
carcinoma of the prostate. Estrogen therapy is an effective alter-
native, but its significant cardiovascular side effects should rele-
gate this mode of therapy to a secondary role. LHRH analogs are 
excellent altematives to orchiectomy, are well tolerated, and 
therefore should be considered as the next best altemative to or-
chiectomy. No evidence exists to support the concept of total an-
drogen ablation. While antiandrogens are effective modalities of 
treatment, they are not superior to standard therapy and thus 
should remain secondary to primary hormonal ablation. Their 
possibly more important role is to provide symptomatic relief 
for patients in whom primary hormonal therapy has failed. 
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